Exciting new treatment approaches for pathyphysiologic mechanisms of sickle cell disease

Pediatric Pathology and Molecular Medicine

Volumn 20, Issue 1, 2001, Pages 1-13

  Mankad, V N ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Bone marrow transplation; Butyrate; Clotrimazole; Gene therapy; Hydroxyurea; Nitric oxide; Poloxamer 188; Sickle cell anemia disease

Indexed keywords

ANTICOAGULANT AGENT; BILIRUBIN; BUTYRIC ACID; CLOTRIMAZOLE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLOBIN; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; LACTATE DEHYDROGENASE; MAGNESIUM; NITRIC OXIDE; PENICILLIN G; POLOXAMER; THROMBOCYTE ACTIVATING FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ALOPECIA; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DYSURIA; GENE THERAPY; GLOBIN GENE; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERPIGMENTATION; LUNG DISEASE; MUCOSA INFLAMMATION; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SKIN ATROPHY; STREPTOCOCCUS INFECTION; UREMIA; VERTIGO; ADULT; ANIMAL; CHEMICALLY INDUCED DISORDER; CHILD; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; DISEASE MODEL; ISCHEMIA; LEUKEMIA; MOUSE; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; RISK; THROMBOSIS; TRANSGENIC MOUSE;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANEMIA, SICKLE CELL; ANIMALS; CHILD; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; ISCHEMIA; LEUKEMIA; MICE; MICE, TRANSGENIC; RANDOMIZED CONTROLLED TRIALS; RISK; THROMBOSIS;

EID: 0035110628     PISSN: 15227952     EISSN: None     Source Type: Journal    
DOI: 10.1080/15227950150502501     Document Type: Review

References (50)

1. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia
2. 5-Azacytidine increases gamma globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia
3. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia
4. Stimulation of F-cell production in patients with sickle cell anemia treated with cytarabine or hydroxyurea
5. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea
6. Relationship of burst forming unit erythroid progenitors and their DNA synthesis stage to fetal hemoglobin levels in dydroxyurea treated patients with sickle cell anemia
7. The effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo
8. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia
9. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
10. Prediction of adverse outcomes in children with sickle cell disease
11. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells
12. Hydroxyurea therapy in children severely affected with sickle cell disease
13. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial
14. Clinical and hematological effects of hydroxyurea in children with sickle cell anemia
15. Hydroxyurea in children with sickle cell disease: Impact on splenic function and compliance with therapy
16. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial
17. Effects of hydroxyurea in very young children with sickle cell disease: A pilot trial
18. Adverse effects of hydroxyurea on growth and development of young mice
19. Acute leukemia after hydroxyurea therapy in polycythemia and allied disorders: Prospective study of efficacy and leukemogenicity with therapeutic implications
20. Treatment of polycythemia vera: A summary of the clinical trials conducted by the Polycythemia Vera Study Group
21. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease
22. Cytogenetic and molecular (p53 and ras) studies in sickle cell patients receiving hydroxyurea over long periods do not indicate an increased risk for leukemia
23. Acquired DNA mutations associated with in vivo hydroxyurea exposure
24. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: Splenic regeneration
25. Lack of improvement in organ function in older children with sickle cell anemia treated with hydroxyurea
26. Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia
27. A cautionary note regarding hydroxyurea in sickle cell disease
28. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease
29. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
30. A short term trial of butyrate to stimulate fetal globin gene expression in the beta globin disorders
31. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
32. Erythroid progenitor proliferation is stimulated by phenoxyacetic and phenylalkyl acids
33. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
34. Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids
35. Therapy with oral clotrimazole induces inhibition of the Gardos Channel and reduction of erythrocyte dehydration in patients with sickle cell disease
36. Inhibition of K transport by divalent cations in sickle erythrocytes
37. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease
38. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease; a pilot study
39. Monoclonal antibodies to αVβ3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet activating factor
40. Introduction: Anti-adhesion therapy in sickle cell disease
41. Long term anticoagulation in sickle cell disease
42. Low intensity oral anticoagulation in sickle cell disease
43. Low concentration of nitric oxide increases oxygen affinity of sickle erythrocytes in vitro and in vivo
44. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity
45. Endothelial cell nitric oxide production in acute chest syndrome
46. Can we just say NO to sickle cell anemia
47. Bone marrow transplantation for beta-thalassemia
48. Impact of bone marrow transplantation for symptomatic sickle cell disease, an interim report
49. Genetic correction of sickle cell disease: Insights using transgenic mouse models
50. The first step on the gene therapy pathway to anti-sickling success